Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 21 June 2016 Biocartis launches advanced EGFR Mutation Assay detecting over 50 mutations Important addition to Biocartis’ core oncology menu now covering most known and used oncology biomarkers Non-regulated information 1 June 2016 Idylla™ Ebola Virus Triage Test Granted Emergency Use Authorization by U.S. FDA Non-regulated information 23 May 2016 Study demonstrating Biocartis’ BRAF liquid biopsy assay... Test can predict therapy response over the course of the cancer treatment Non-regulated information 26 April 2016 Biocartis Strengthens Biomarker Portfolio for Colorectal Cancer Exclusive license of recently detected EGFR resistance mutations Non-regulated information 3 February 2016 Biocartis & Amgen Collaborate to Offer Rapid RAS Biomarker Testing to Selected Hospitals and Clinics... Non-regulated information 7 January 2016 Biocartis & Merck to Collaborate on New Liquid Biopsy Technology for RAS Biomarker Testing Non-regulated information 22 December 2015 Biocartis launches world’s first fully automated liquid biopsy assay and its second tissue assay for colorectal cancer Launch of two new tests on its Idylla™ molecular diagnostics platform strengthens the company’s assay menu Non-regulated information 16 December 2015 Biocartis announces financial calendar 2016 Non-regulated information 30 November 2015 Biocartis announces launch of Influenza-Respiratory Virus Panel on the Idylla™ platform Non-regulated information 3 November 2015 Biocartis participate in key IR conferences in November 2015 Non-regulated information Pagination First page « First Previous page ‹‹ … Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Current page 11 Page 12 Next page ›› Last page Last »